Clinical trial · Observational
Primary Hepatobiliary Cancer Cohort of Central China
The Treatment and Prognosis of Primary Hepatobiliary Cancer: A Cohort Study in Central China
NCT05520801CI-TRIAL-00072394CCGLC-002unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This registry is designed as a longitudinal cohort study of patients diagnosed with primary hepatobiliary cancer in Tongji Hospital, Wuhan. This study collects the clinical-pathological features of hepatic malignant tumors and the current status of patients who received comprehensive treatment based on surgical treatment since 1998.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Biliary Tract Neoplasms | — | UNRESOLVED | — |
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Overall Survival (OS)
- timeFrame
- From diagnosis or treatment initiation to date of death due to any cause, or last known vital status date, up to 2 years
- description
- Time of death will be obtained by telephone interview or medical treatment records.
- measure
- Progression-free survival (PFS)
- timeFrame
- From treatment initiation for advanced or metastatic HCC to the first date of disease progression for any cause up to 2 years
- description
- Patients lost for follow up or withdrawn from the study will be censored at the last disease assessment date
- measure
- Disease Control Rate (DCR)
- timeFrame
- From treatment initiation to SD, CR or PR, up to 2 years
- description
- The proportion of patients who had either stable disease (SD) for ≥ 6 months, a CR or PR after initiation of treatment for HCC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. ≥18 years old, 2. life expectancy is at least 6 months. 3. Diagnosed as primary liver cancer or biliary malignant tumor by histopathology or confirmed by imaging as HCC (by the AASLD or guidance for the diagnosis and treatment of primary liver cancer of China (version 2022). 4. At least one measurable lesion (RECIST v1.1) 5. Subjects volunteer to participate in the study and sign informed consent. Exclusion Criteria: Patients with one or more of the following criteria should be excluded: 1. CT or MRI shows no measurable lesions (RECIST v1.1). 2. Patients after comprehensive assessment are considered by the investigators to be unsuitable for participating in the study. 3. Incomplete baseline or follow-up data 4. Suffering from more than two kinds of primary tumors
References
Publications (0)
Data not yet available
No reference posted for this study.